Patient | Step | No. of CTC detected (/7.5 ml) | No. of CTC with FISH | No. of HER2amp CTC | HER2 and CEP17 for each HER2amp CTC | ||
---|---|---|---|---|---|---|---|
N CEP17 | N HER2 | HER2/CEP17 ratio | |||||
Patients screened with HER2amp CTC, with no further sample (not treated or not assessed) | |||||||
03-020-1 | Screening | 9 | 2 | 1 | 1 | 3 | 3.0 |
03-030-1 | Screening | 247 | 61 | 1 | 1 | 3 | 3.0 |
03-031-1 | Screening | 69 | 28 | 1 | 2 | 6 | 3.0 |
03-039-1 | Screening | 111 | 19 | 1 | 1 | 7 | 7.0 |
04-003-1 | Screening | 30 | 8 | 1 | 2 | 6 | 3.0 |
10-004-1 | Screening | 39 | 2 | 1 | 2 | 5 | 2.5 |
03-037-2 | Screening | 308 | 51 | 5 | 2 | 6 | 3.0 |
2 | 6 | 3.0 | |||||
2 | 5 | 2.5 | |||||
2 | 5 | 2.5 | |||||
2 | 5 | 2.5 | |||||
10-005-2 | Screening | 475 | 92 | 6 | 1 | 10 | 10.0 |
1 | 10 | 10.0 | |||||
1 | 8 | 8.0 | |||||
1 | 3 | 3.0 | |||||
2 | 5 | 2.5 | |||||
2 | 5 | 2.5 | |||||
Patients screened with HER2amp CTC with sample during therapy | |||||||
01-017-1 | Screening | 22 | 7 | 2 | 1 | 3 | 3.0 |
1 | 3 | 3.0 | |||||
Cycle #2 | 9 | 5 | 0 | ||||
Progression | 22 | 9 | 0 | ||||
05-005-1 | Screening | 32 | 7 | 2 | 1 | 3 | 3.0 |
1 | 3 | 3.0 | |||||
Cycle #2 | 10 | 6 | 0 | ||||
05-006-2 | Screening | 17 | 10 | 6 | 1 | 3 | 3.0 |
1 | 3 | 3.0 | |||||
1 | 3 | 3.0 | |||||
1 | 3 | 3.0 | |||||
1 | 3 | 3.0 | |||||
1 | 3 | 3.0 | |||||
Cycle #2 | 57 | 31 | 17 | (*) see caption | |||
07-010-1 | Screening | 397 | 167 | 2 | 1 | 5 | 5.0 |
2 | 8 | 4.0 | |||||
Cycle #2 | 445 | 216 | 3 | 2 | 10 | 5.0 | |
3 | 10 | 3.3 | |||||
1 | 3 | 3.0 | |||||
08-001-1 | Screening | 355 | 171 | 1 | 1 | 3 | 3.0 |
Cycle #2 | 136 | 95 | 3 | 1 | 6 | 6.0 | |
2 | 6 | 3.0 | |||||
1 | 3 | 3.0 | |||||
Progression | 665 | 484 | 4 | 1 | 3 | 3.0 | |
1 | 3 | 3.0 | |||||
1 | 3 | 3.0 | |||||
2 | 5 | 2.5 | |||||
08-002-1 | Screening | 275 | 107 | 2 | 1 | 4 | 4.0 |
2 | 5 | 2.5 | |||||
Cycle #2 | 242 | 70 | 5 | 1 | 4 | 4.0 | |
1 | 3 | 3.0 | |||||
1 | 3 | 3.0 | |||||
1 | 3 | 3.0 | |||||
1 | 3 | 3.0 | |||||
1 | 3 | 3.0 |